Skip to main content
NCBI home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1988 Feb;32(2):241–245. doi: 10.1128/aac.32.2.241

Differences in resistance to reinfection with low and high inocula of Trypanosoma cruzi in chagasic mice treated with nifurtimox and relation to immune response.

P Cabeza Meckert 1, J G Chambó 1, R P Laguens 1
PMCID: PMC172142  PMID: 3129986

Abstract

Reinfection of chronic chagasic mice after treatment with nifurtimox resulted in different outcomes according to the number of parasites used for inoculation. Nifurtimox-treated chagasic animals injected with 2,500 trypomastigotes developed higher parasitemia and increased mortality compared with nontreated chagasic mice. When reinfection was done with 25 trypomastigotes, treated and nontreated animals showed similar parasitemias and mortalities, which were significantly higher in nonchagasic controls infected for the first time. Immunological studies showed that treatment with nifurtimox led to a decrease in anti-Trypanosoma cruzi antibodies engaged in parasite destruction, inducing either complement-dependent lysis or antibody-dependent cytotoxicity, but no difference in anti-T. cruzi cell-mediated immunity was found between treated and nontreated chagasic animals. It is concluded that treatment with nifurtimox leads to a loss of resistance to reinfection with a large number of trypanosomes, which is maintained with challenge with a few parasites, and that these two thresholds of premunition are probably associated with humoral and cell-mediated anti-T. cruzi immune responses, respectively.

Full text

PDF
241

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. BRENER Z. Therapeutic activity and criterion of cure on mice experimentally infected with Trypanosoma cruzi. Rev Inst Med Trop Sao Paulo. 1962 Nov-Dec;4:389–396. [PubMed] [Google Scholar]
  2. BRENER Z. [Observations on immunity to superinfections in mice experimentally inoculated with Trypanosoma cruzi and subjected to treatment]. Rev Inst Med Trop Sao Paulo. 1962 Mar-Apr;4:119–123. [PubMed] [Google Scholar]
  3. Cabeza Meckert P., Laguens R. P. Chronic Chagas disease in the mouse: III. Absence of concomitant immunity after repeated infections. Medicina (B Aires) 1981;41(5):543–548. [PubMed] [Google Scholar]
  4. Camargo M. E. Fluorescent antibody test for the serodiagnosis of American trypanosomiasis. Technical modification employing preserved culture forms of Trypanosoma cruzi in a slide test. Rev Inst Med Trop Sao Paulo. 1966 Sep-Oct;8(5):227–235. [PubMed] [Google Scholar]
  5. Kierszenbaum F. Antibody-dependent killing of bloodstream forms of Trypanosoma cruzi by human peripheral blood leukocytes. Am J Trop Med Hyg. 1979 Nov;28(6):965–968. doi: 10.4269/ajtmh.1979.28.965. [DOI] [PubMed] [Google Scholar]
  6. Krettli A. U., Brener Z. Resistance against Trypanosoma cruzi associated to anti-living trypomastigote antibodies. J Immunol. 1982 May;128(5):2009–2012. [PubMed] [Google Scholar]
  7. Krettli A. U., Cançado J. R., Brener Z. Effect of specific chemotherapy on the levels of lytic antibodies in Chagas's disease. Trans R Soc Trop Med Hyg. 1982;76(3):334–340. doi: 10.1016/0035-9203(82)90184-5. [DOI] [PubMed] [Google Scholar]
  8. Laguens R. P., Cabeza Meckert P., Basombrío M. A., Chambó G. J., Cossio P. M., Arana R. M., Gelpi R. Infección crónica del ratón con Tryupanosoma cruzi. Modelo experimental de enfermedad de Chagas. Medicina (B Aires) 1980;40 (Suppl 1):33–39. [PubMed] [Google Scholar]
  9. Lelchuk R., Cardoni R. L., Fuks A. S. Cell-mediated immunity in Chagas' disease: Alterations induced by treatment with a trypanocidal drug (nifurtimox). Clin Exp Immunol. 1977 Dec;30(3):434–438. [PMC free article] [PubMed] [Google Scholar]
  10. Menezes H. Aplicaço de vacina viva avirulenta de Trypanosoma cruzi em séres humanos (nota prévia) Rev Inst Med Trop Sao Paulo. 1971 Mar-Apr;13(2):144–154. [PubMed] [Google Scholar]
  11. Neal R. A., Miles R. A. Indirect haemagglutination test for Chagas' disease, with a simple method for survey work. Rev Inst Med Trop Sao Paulo. 1970 Sep-Oct;12(5):325–332. [PubMed] [Google Scholar]
  12. Ruiz A. M., Esteva M., Cabeza Meckert P., Laguens R. P., Segura E. L. Protective immunity and pathology induced by inoculation of mice with different subcellular fractions of Trypanosoma cruzi. Acta Trop. 1985 Dec;42(4):299–309. [PubMed] [Google Scholar]
  13. Scott M. T., Snary D. Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi. Nature. 1979 Nov 1;282(5734):73–74. doi: 10.1038/282073a0. [DOI] [PubMed] [Google Scholar]
  14. Segura E. L., Cura E. N., Paulone I., Vasquez C., Cerisola J. A. Antigenic makeup of subcellular fractions of Trypanosoma cruzi. J Protozool. 1974 Oct;21(4):571–574. doi: 10.1111/j.1550-7408.1974.tb03703.x. [DOI] [PubMed] [Google Scholar]
  15. Snary D. Cell surface glycoproteins of Trypanosoma cruzi: protective immunity in mice and antibody levels in human chagasic sera. Trans R Soc Trop Med Hyg. 1983;77(1):126–129. doi: 10.1016/0035-9203(83)90037-8. [DOI] [PubMed] [Google Scholar]
  16. Trischmann T. M., Bloom B. R. Trypanosoma cruzi: ability of T-cell-enriched and -depleted lymphocyte populations to passively protect mice. Exp Parasitol. 1980 Apr;49(2):225–232. doi: 10.1016/0014-4894(80)90119-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES